AVIL

Across TCGA pan-cancer cohorts, AVIL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AVIL data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AVIL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AVIL expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where AVIL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.996	0.715	<.001	66	view →
HNSC	DFS	Tertile	II,III,IV	0.826	0.409	.001	22	view →
GBM	OS	Median	All	0.208	0.740	.038	6	view →
LSCC	DFS	Median	All	0.892	0.190	.024	4	view →
LUAD	OS	Median	All	1.000	0.912	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AVIL–PDAC (OS)

Open the PDAC breakdown →